Education
About Us
Working with TipRanks
Follow Us
Belite Bio, Inc. ADR (BLTE)
NASDAQ:BLTE
Earnings Data
Report Date
Aug 06, 2025TBA Not Confirmed
Period Ending
2025 (Q2)Consensus EPS Forecast
-0.39Last Year’s EPS
-0.31Same Quarter Last Year
Strong Buy
Based on 5 Analysts Ratings
Earnings Call Summary
Earnings Call Date:May 14, 2025
|% Change Since: 6.45%
|Next Earnings Date:Aug 06, 2025
Earnings Call Sentiment|Positive
The earnings call presented a generally positive outlook for Belite Bio, with significant progress in clinical trials for Tinlarebant and a robust financial position. However, increased operating expenses and pending regulatory details introduce some uncertainty.Company Guidance
During the Belite Bio First Quarter 2025 Earnings Call, the company provided several key metrics and updates regarding their clinical trials and financial standing. In the Stargardt disease program, the Phase 3 DRAGON trial, involving 104 subjects, has moved forward successfully with the Data Safety Monitoring Board (DSMB) recommending no changes to the trial size and suggesting data submission for regulatory review. The DRAGON 2 trial has enrolled 16 out of a targeted 60 subjects. For geographic atrophy, the Phase 3 PHOENIX trial has enrolled 464 subjects out of a planned 500, with full enrollment expected by Q3 2025. Financially, the company reported R&D expenses of $9.4 million and G&A expenses of $6.1 million for Q1 2025, resulting in a net loss of $14.3 million. Despite the increased expenses, primarily due to share-based compensation, Belite Bio maintains a strong financial position with $157.4 million in cash and equivalents, ensuring a cash runway to complete current clinical trials.Promising Clinical Progress for Tinlarebant
The Phase 3 DRAGON trial for Tinlarebant showed promising interim results with the DSMB recommending submission for further regulatory review. The trial is on track for completion by the end of the year.
Strong Financial Position
Belite Bio reported a cash increase of $12.3 million for the quarter, leaving the company with $157.4 million in cash and equivalents. The company expects a full year cash runway to complete all current clinical trials.
Phase 3 PHOENIX Trial Advancements
The PHOENIX trial for geographic atrophy has enrolled 464 subjects with a total target of 500. Enrollment is expected to be completed in Q3 2025.
Low Withdrawal Rates in Clinical Trials
DRAGON trial showed less than a 10% overall withdrawal rate, and the PHOENIX trial's dropout rate is approximately 20%, which is lower than comparables.
BLTE Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
BLTE Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 14, 2025 | $60.89 | $61.60 | +1.17% |
Mar 17, 2025 | $67.44 | $67.81 | +0.55% |
Nov 12, 2024 | $78.64 | $81.15 | +3.19% |
Aug 09, 2024 | $49.48 | $48.55 | -1.88% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Belite Bio, Inc. ADR (BLTE) report earnings?
Belite Bio, Inc. ADR (BLTE) is schdueled to report earning on Aug 06, 2025, TBA Not Confirmed.
What is Belite Bio, Inc. ADR (BLTE) earnings time?
Belite Bio, Inc. ADR (BLTE) earnings time is at Aug 06, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is BLTE EPS forecast?
BLTE EPS forecast for the fiscal quarter 2025 (Q2) is -0.39.